To the Editor: Drs Pogach and Aron1 used the Toyota example of failure to quickly “pull the cord” at the first sign of a safety or quality problem to suggest leading guideline and measure development organizations did not respond to changing evidence on control of glycated hemoglobin (HbA1c) levels in patients with diabetes. In fact, the National Committee for Quality Assurance (NCQA) did respond quickly when the National Institutes of Health suspended the ACCORD (Action to Control Cardiovascular Risk in Diabetes) study2 intervention group in February 2008 and the ACCORD and ADVANCE3 (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) studies were published later that year.
O’Kane ME, Pawlson G. Diabetes Quality Measures. JAMA. 2011;305(19):1966-1968. doi:10.1001/jama.2011.642